Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Spero Therapeutics (SPRO) over the last 10 years, with Q3 2025 value amounting to $27.7 million.

  • Spero Therapeutics' Total Liabilities fell 6026.65% to $27.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.7 million, marking a year-over-year decrease of 6026.65%. This contributed to the annual value of $64.4 million for FY2024, which is 1467.1% down from last year.
  • According to the latest figures from Q3 2025, Spero Therapeutics' Total Liabilities is $27.7 million, which was down 6026.65% from $29.3 million recorded in Q2 2025.
  • Spero Therapeutics' 5-year Total Liabilities high stood at $83.4 million for Q1 2022, and its period low was $24.6 million during Q1 2021.
  • For the 5-year period, Spero Therapeutics' Total Liabilities averaged around $50.4 million, with its median value being $47.7 million (2023).
  • Its Total Liabilities has fluctuated over the past 5 years, first surged by 28663.77% in 2021, then crashed by 6026.65% in 2025.
  • Quarter analysis of 5 years shows Spero Therapeutics' Total Liabilities stood at $82.8 million in 2021, then tumbled by 40.97% to $48.9 million in 2022, then soared by 54.49% to $75.5 million in 2023, then fell by 14.67% to $64.4 million in 2024, then tumbled by 57.04% to $27.7 million in 2025.
  • Its Total Liabilities stands at $27.7 million for Q3 2025, versus $29.3 million for Q2 2025 and $43.9 million for Q1 2025.